CD8A and cancer: In summary, the real-time quantitative evaluation of defined intratumoral immune cell populations using a clinically validated assay, particularly the enumeration of CD8+, PD-1+, and CD8+PD-1+ cells, provides prognostic information across various cancer types, independent of the current staging and risk assessment systems.